Predicate Research Report · generated 2026-08-22 · Print / save as PDF · Save to account
Syva Co., Dade Behring, Inc. — Predicate Candidate Screening
19 FDA 510(k) clearances under this manufacturer; the 50 most recent screened below.
24 daysmedian FDA review time
33 days90th percentile
19clearances measured
| K-number | Device | Applicant | Decided | Review days | Recalls (K-match) |
|---|---|---|---|---|---|
| K011920 | EMIT 2000 DIGOXIN ASSAY, MODEL OSR4H229 | Syva Co., Dade Behring, Inc. | 2001-07-02 | 12 | 0 |
| K011620 | EMIT 2000 N-ACETYLPROCAINAMIDE ASSAY, MODEL OSR4N229 | Syva Co., Dade Behring, Inc. | 2001-06-18 | 24 | 0 |
| K011605 | EMIT 2000 QUINIDINE ASSAY, MODEL OSR4Q229 | Syva Co., Dade Behring, Inc. | 2001-06-12 | 19 | 0 |
| K011300 | EMIT II PLUS CANNABINOID ASSAY, MODEL OSR9N229 | Syva Co., Dade Behring, Inc. | 2001-05-17 | 17 | 0 |
| K011306 | EMIT II PLUS BENZODIAZEPINE ASSAY, MODEL 0SR9F229 | Syva Co., Dade Behring, Inc. | 2001-05-16 | 16 | 0 |
| K011161 | MODIFICATION TO THE EMIT II PLUS PHENCYCLIDINE ASSAY, MODEL | Syva Co., Dade Behring, Inc. | 2001-05-15 | 29 | 0 |
| K011289 | EMIT II PLUS OPIATE ASSAY, MODEL OSR9B229 | Syva Co., Dade Behring, Inc. | 2001-05-15 | 18 | 0 |
| K011166 | MODIFICATION TO EMIT 2000 THEOPHYLLINE ASSAY, MODEL OSR 4P22 | Syva Co., Dade Behring, Inc. | 2001-05-10 | 24 | 0 |
| K011163 | MODIFICATION TO THE EMIT II PLUS PROPOXYPHENE ASSAY, MODEL O | Syva Co., Dade Behring, Inc. | 2001-05-10 | 24 | 0 |
| K011164 | MODIFICATION TO THE EMIT II PLUS METHAQUALONE ASSAY, MODEL O | Syva Co., Dade Behring, Inc. | 2001-05-10 | 24 | 0 |
| K011162 | MODIFICATION TO THE EMIT II PLUS COCAINE METABOLITE ASSAY | Syva Co., Dade Behring, Inc. | 2001-05-02 | 16 | 0 |
| K010960 | EMIT II PLUS ETHYL ALCOHOL ASSAY, MODEL OSR9K229 | Syva Co., Dade Behring, Inc. | 2001-04-26 | 27 | 0 |
| K010962 | EMIT II PLUS METHADONE ASSAY, MODEL OSRE229 | Syva Co., Dade Behring, Inc. | 2001-04-26 | 27 | 0 |
| K010934 | EMIT II PLUS BARBITUATE ASSAY, MODEL 0SR9D0229 | Syva Co., Dade Behring, Inc. | 2001-04-20 | 23 | 0 |
| K010984 | EMIT 2000 GENTAMICIN PLUS ASSAY | Syva Co., Dade Behring, Inc. | 2001-04-20 | 18 | 0 |
| K010812 | EMIT 2000 PROCAINAMIDE ASSAY, MODEL OSR4K229 | Syva Co., Dade Behring, Inc. | 2001-04-13 | 25 | 0 |
| K010814 | EMIT 2000 CARBAMAZEPINE ASSAY, MODEL OSR4F229 | Syva Co., Dade Behring, Inc. | 2001-04-13 | 25 | 0 |
| K003341 | EMIT 2000 TOBRAMYCIN ASSAY EMIT 2000 TOBRAMYCIN CALIBRATORS | Syva Co., Dade Behring, Inc. | 2001-01-22 | 89 | 0 |
| K000600 | SYVA EMIT 2000 THYROXINE ASSAY, CALIBRATORS | Syva Co., Dade Behring, Inc. | 2000-03-27 | 33 | 0 |
Methodology
Recall counts reflect FDA recall records explicitly referencing each K-number; FDA links recalls to K-numbers inconsistently, so 0 means "none found in FDA records," not "never recalled." Data: FDA openFDA, refreshed weekly. Verify decisions of consequence against the primary source. Full candidate set and CSV export: atlasbyauro.com.
Prepared with Atlas
Predicate research, review-time statistics and recall monitoring for 510(k) teams — atlasbyauro.com/fda